Drug Device Combination Market Key Trends, Business Overview, Growth Objectives Forecast 2033

Overview and Scope

Drug-device combination refers to therapeutic and diagnostic products that associate a medical device with a drug for local administration of the drug, precise drug targeting, and individualized therapy. These are physically and chemically combined to produce a single entity and packaged together in a single package. The drug-device combination is used in clinical development to deliver drugs to the desired location in the body.

Sizing and Forecast
The drug device combination market size has grown rapidly in recent years. It will grow from $120.37 billion in 2023 to $134.41 billion in 2024 at a compound annual growth rate (CAGR) of 11.7%.  The  growth in the historic period can be attributed to increasing medical innovation, rise in chronic diseases, patient-centric approaches, advances in biologics, challenges of monotherapy,clinical needs..

The drug device combination market size is expected to see rapid growth in the next few years. It will grow to $205.86 billion in 2028 at a compound annual growth rate (CAGR) of 11.2%.  The growth in the forecast period can be attributed to patient empowerment and engagement, healthcare digitalization, global market expansion, emergence of novel therapies, value-based healthcare. Major trends in the forecast period include therapeutic advancements, complex disease management, patient-centric care, technological innovations, regulatory support..

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/drug-device-combination-global-market-report

The drug device combination market covered in this report is segmented –

1) By Product: Auto-Injector, Microneedle Patch, Digital Pill, Smart Inhaler, Drug Delivery Hydrogels, Drug-Eluting Lens, Other Products
2) By Distribution Channel: Direct Tender, Retails Sales, Other Distribution Channels
3) By Application: Orthopedic Diseases, Respiratory Diseases, Diabetes, Oncology, Cardiovascular Diseases, Other Applications
4) By End User: Clinics, Hospitals, Home Care Settings, Ambulatory Care Centers, Other End Users

North America was the largest region in the drug-device combination market share in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug device combination market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=8206&type=smp

Major Driver Impacting Market Growth

The increasing prevalence of chronic diseases is anticipated to drive the drug-device combination market. Chronic disease refers to a type of disease that persists for a year or longer, impedes everyday activities, necessitates continuing medical care, or both. Chronic disease includes heart disease, diabetes, and so on. Drug device combinations are therapeutic and diagnostic products that lead to effective treatment of people suffering from chronic diseases. For instance, according to a report by the World Health Organization, a specialized body of the United Nations to ensure international public health, in 2022, diabetes affected more than 420 million individuals globally. By 2030 and 2045, these numbers are expected to increase to 578 million and 700 million, respectively. Hence, the increasing prevalence of chronic diseases is driving the growth of the drug-device combination market.

Key Industry Players

Major companies operating in the drug device combination market report are The 3M Company, Abbott India Ltd., Biotronik SE & Co. KG, Boston Scientific Corporation, C. R. Bard Inc., Medtronic plc, Amgen Inc., Ypsomed Holding AG, Micron Biomedical Inc., MetP Pharma AG, Sonceboz SA, Propeller Health B.D. Inc., Lepu Medical Technology (Beijing) Co. Ltd., Eitan Medical Ltd., Vaxess Technologies Inc., Subcuject Aps, Allergan plc, Terumo Corporation, Stryker Corporation, Becton Dickinson and Company, Novartis AG, Zimmer Biomet Holdings Inc., MediPrint Ophthalmics, Arrow International Inc., Alcon Inc., W. L. Gore & Associates Inc., Cook Medical LLC, Pinnacle Biologics Inc., GlaxoSmithKline plc, Mylan N.V.

The drug device combination market report table of contents includes:

1. Executive Summary

2. Drug Device Combination Market Characteristics

3. Drug Device Combination Market Trends And Strategies

4. Drug Device Combination Market – Macro Economic Scenario

…

31. Global Drug Device Combination Market Competitive Benchmarking

32. Global Drug Device Combination Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Drug Device Combination Market

34. Drug Device Combination Market Future Outlook and Potential Analysis

 

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model